Visualizing Neighborhood COVID-19 Levels, Trends, and Inequities in Wastewater: An Equity-Centered Approach and Comparison to CDC Methods.
Saved in:
| Title: | Visualizing Neighborhood COVID-19 Levels, Trends, and Inequities in Wastewater: An Equity-Centered Approach and Comparison to CDC Methods. |
|---|---|
| Authors: | Cowger TL; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Link NB; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Hart JD; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Sharp MT; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Nair S; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Balasubramanian R; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Moallef S; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Chen J; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Hanage WP; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Tabb LP; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Hall KT; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Ojikutu BO; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Krieger N; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Bassett MT; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support. |
| Source: | Journal of public health management and practice : JPHMP [J Public Health Manag Pract] 2025 Mar-Apr 01; Vol. 31 (2), pp. 270-282. Date of Electronic Publication: 2024 Sep 10. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9505213 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1550-5022 (Electronic) Linking ISSN: 10784659 NLM ISO Abbreviation: J Public Health Manag Pract Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39254302 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Visualizing Neighborhood COVID-19 Levels, Trends, and Inequities in Wastewater: An Equity-Centered Approach and Comparison to CDC Methods. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Cowger+TL%22">Cowger TL</searchLink>; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support.<br /><searchLink fieldCode="AU" term="%22Link+NB%22">Link NB</searchLink>; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support.<br /><searchLink fieldCode="AU" term="%22Hart+JD%22">Hart JD</searchLink>; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support.<br /><searchLink fieldCode="AU" term="%22Sharp+MT%22">Sharp MT</searchLink>; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support.<br /><searchLink fieldCode="AU" term="%22Nair+S%22">Nair S</searchLink>; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support.<br /><searchLink fieldCode="AU" term="%22Balasubramanian+R%22">Balasubramanian R</searchLink>; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support.<br /><searchLink fieldCode="AU" term="%22Moallef+S%22">Moallef S</searchLink>; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support.<br /><searchLink fieldCode="AU" term="%22Chen+J%22">Chen J</searchLink>; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support.<br /><searchLink fieldCode="AU" term="%22Hanage+WP%22">Hanage WP</searchLink>; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support.<br /><searchLink fieldCode="AU" term="%22Tabb+LP%22">Tabb LP</searchLink>; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support.<br /><searchLink fieldCode="AU" term="%22Hall+KT%22">Hall KT</searchLink>; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support.<br /><searchLink fieldCode="AU" term="%22Ojikutu+BO%22">Ojikutu BO</searchLink>; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support.<br /><searchLink fieldCode="AU" term="%22Krieger+N%22">Krieger N</searchLink>; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support.<br /><searchLink fieldCode="AU" term="%22Bassett+MT%22">Bassett MT</searchLink>; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229505213%22">Journal of public health management and practice : JPHMP</searchLink> [J Public Health Manag Pract] 2025 Mar-Apr 01; Vol. 31 (2), pp. 270-282. <i>Date of Electronic Publication: </i>2024 Sep 10. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lippincott+Williams+%26+Wilkins%22">Lippincott Williams & Wilkins </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9505213 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1550-5022 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210784659%22">10784659 </searchLink><i>NLM ISO Abbreviation: </i>J Public Health Manag Pract <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39254302 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1097/PHH.0000000000002049 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 270 Titles: – TitleFull: Visualizing Neighborhood COVID-19 Levels, Trends, and Inequities in Wastewater: An Equity-Centered Approach and Comparison to CDC Methods. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Cowger TL – PersonEntity: Name: NameFull: Link NB – PersonEntity: Name: NameFull: Hart JD – PersonEntity: Name: NameFull: Sharp MT – PersonEntity: Name: NameFull: Nair S – PersonEntity: Name: NameFull: Balasubramanian R – PersonEntity: Name: NameFull: Moallef S – PersonEntity: Name: NameFull: Chen J – PersonEntity: Name: NameFull: Hanage WP – PersonEntity: Name: NameFull: Tabb LP – PersonEntity: Name: NameFull: Hall KT – PersonEntity: Name: NameFull: Ojikutu BO – PersonEntity: Name: NameFull: Krieger N – PersonEntity: Name: NameFull: Bassett MT IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: 2025 Mar-Apr 01 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1550-5022 Numbering: – Type: volume Value: 31 – Type: issue Value: 2 Titles: – TitleFull: Journal of public health management and practice : JPHMP Type: main |
| ResultId | 1 |
